Critical reviews in oncology/hematology最新文献

Glioblastoma: Molecular features, emerging molecular targets and novel therapeutic strategies 胶质母细胞瘤：分子特征，新出现的分子靶点和新的治疗策略

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-05-12 DOI: 10.1016/j.critrevonc.2025.104764

Anastasios Politis , Lampis Stavrinou , Aristotelis Kalyvas , Efstathios Boviatsis , Christina Piperi

{"title":"Glioblastoma: Molecular features, emerging molecular targets and novel therapeutic strategies","authors":"Anastasios Politis , Lampis Stavrinou , Aristotelis Kalyvas , Efstathios Boviatsis , Christina Piperi","doi":"10.1016/j.critrevonc.2025.104764","DOIUrl":"10.1016/j.critrevonc.2025.104764","url":null,"abstract":"<div><div>Glioblastomas (GBMs) constitute the most common malignant tumors of the Central Nervous System (CNS) with a complex molecular, genetic and histological profile and extensive heterogenicity. GBMs are notoriously difficult to treat, with morbidity and mortality rate that remain high and practically unchanged, despite the aggressive and multimodal treatment strategies. Keeping up with current research and emerging scientific data is of primary importance for the detection of new molecular targets, enabling the design of novel therapeutic strategies. Herein, we discuss current data on the cellular and molecular features that contribute to GBM pathophysiological mechanisms in an effort to reveal emerging molecular targets with therapeutic potential as well as effective immunotherapeutic approaches, including chimeric antigen receptor (CAR) T-cell therapy and adaptive immune modulation with immune checkpoint inhibitors. Enhanced drug delivery strategies such as ultrasound-assisted technologies to overcome drug resistance are also discussed, aiming to provide an overall translational perspective that bridges molecular insights with practical therapeutic implications.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104764"},"PeriodicalIF":5.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subtypes of tumor-associated neutrophils and their roles in cancer immunotherapy 肿瘤相关中性粒细胞亚型及其在癌症免疫治疗中的作用

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-05-05 DOI: 10.1016/j.critrevonc.2025.104763

Xinyun Chu , Ning Pu , Xue Yang , Yuqi Xie , Liang Liu , Yun Jin

引用次数: 0

Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls 新型驱动改变非小细胞肺癌的生物制剂：潜力和缺陷

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-05-03 DOI: 10.1016/j.critrevonc.2025.104748

Gianluca Russo , Claudia Scimone , Lucia Palumbo , Giuseppina Roscigno , Claudia Sarracino , Ilaria Tomaiuolo , Pasquale Pisapia , Francesco Pepe , Danilo Rocco , Cesare Gridelli , Giancarlo Troncone , Umberto Malapelle

{"title":"Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls","authors":"Gianluca Russo , Claudia Scimone , Lucia Palumbo , Giuseppina Roscigno , Claudia Sarracino , Ilaria Tomaiuolo , Pasquale Pisapia , Francesco Pepe , Danilo Rocco , Cesare Gridelli , Giancarlo Troncone , Umberto Malapelle","doi":"10.1016/j.critrevonc.2025.104748","DOIUrl":"10.1016/j.critrevonc.2025.104748","url":null,"abstract":"<div><div>Precision medicine has revolutionized clinical paradigm of lung cancer (LC) patients optimizing therapeutical options on the basis of molecular fingerprinting of tumor cells. The advent of the genomic era contributed to the widespread diffusion of sequencing technologies laying the basis for the approval of an increasing number of clinically relevant predictive biomarkers in clinical settings. In the rapidly evolving scenario of predictive biomarkers, mandatory testing genes demonstrated a statistically significant clinical benefit in LC patients elected to molecular tests, but emerging biomarkers are under investigation to raise the bar in the clinical management of LC patients. To date, promising IHC-based predictive biomarkers emerged as potentially integrative tools in the panel of clinically approved biomarkers. On this basis, genomic, transcriptomic and proteomic data are gaining ground toward “3D” biology” supporting the need of a multidimensional analysis of tumor cells to clinically stratify LC patients. Here we sought to overview the most promising biomarkers investigated in clinical trials to be integrated into diagnostic panel of predictive biomarkers tools for NSCLC patients.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104748"},"PeriodicalIF":5.5,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations 携带常见EGFR激活突变的晚期非小细胞肺癌的不断发展的治疗方法

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-05-03 DOI: 10.1016/j.critrevonc.2025.104762

Igor Gomez-Randulfe , Federico Monaca , David Planchard , Emilio Bria , Raffaele Califano

{"title":"Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations","authors":"Igor Gomez-Randulfe , Federico Monaca , David Planchard , Emilio Bria , Raffaele Califano","doi":"10.1016/j.critrevonc.2025.104762","DOIUrl":"10.1016/j.critrevonc.2025.104762","url":null,"abstract":"<div><div>A clinically important subgroup of non-small cell lung cancer (NSCLC) is driven by common mutations in the epidermal growth factor receptor (EGFR). Over the past decade, first-, second-, and third-generation EGFR tyrosine kinase inhibitors (TKIs) have substantially improved clinical outcomes, although acquired resistance inevitably emerges. In particular, the third-generation TKI osimertinib has demonstrated superior progression-free survival (PFS) and overall survival (OS) compared to earlier-generation TKIs in the frontline setting, yet median OS remains approximately three years in pivotal trials. Efforts to extend disease control have led to various upfront intensification strategies, including combining EGFR TKIs with antiangiogenics or chemotherapy (e.g., the FLAURA-2 trial), and pairing novel bispecific antibodies such as amivantamab with third-generation TKIs. Upon progression on third-generation EGFR TKIs, platinum-based chemotherapy remains the standard second-line treatment, albeit with modest response rates. Emerging therapies targeting MET amplification (e.g., savolitinib plus osimertinib), leveraging antibody–drug conjugates (e.g., patritumab deruxtecan), or adding immunotherapy and antiangiogenics have shown preliminary promise in overcoming resistance. Ongoing trials are assessing optimal treatment sequencing and the use of circulating tumor DNA (ctDNA) to guide therapy escalation or de-escalation. Ultimately, the evolving landscape of EGFR-mutant NSCLC underscores the need for refined biomarker-driven approaches and personalized regimens to achieve further gains in survival. In this review, we discuss these strategies in detail, highlighting current evidence and future directions for EGFR-mutant NSCLC treatment.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104762"},"PeriodicalIF":5.5,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143928206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent development in bispecific antibody immunotherapy for hematological malignancies 恶性血液病双特异性抗体免疫治疗的最新进展

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-05-02 DOI: 10.1016/j.critrevonc.2025.104752

Lijie Han , Ke Wang , Zhongxing Jiang , Xuejun Guo , Jifeng Yu

{"title":"Recent development in bispecific antibody immunotherapy for hematological malignancies","authors":"Lijie Han , Ke Wang , Zhongxing Jiang , Xuejun Guo , Jifeng Yu","doi":"10.1016/j.critrevonc.2025.104752","DOIUrl":"10.1016/j.critrevonc.2025.104752","url":null,"abstract":"<div><div>While monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment, challenges such as resistance mechanisms and tumor progression via alternative pathways underscore the need for novel therapeutic strategies. Bispecific antibodies (BsAbs), which target two distinct antigens simultaneously, represent a promising next-generation solution, improving therapeutic precision, efficacy, and safety. BsAbs also redirect cytotoxic effector cells to tumor sites, providing additional therapeutic mechanisms. Recent advancements in BsAb design, such as enhancements in pharmacokinetics and modular multi-specific formats, are expanding their use in hematological malignancies. Combining BsAbs with immune checkpoint inhibitors and other therapies may overcome resistance and improve clinical outcomes. Leading BsAbs, including mosunetuzumab, glofitamab, and blinatumomab, have demonstrated promising efficacy in clinical trials for leukemia and lymphoma subtypes. Despite remaining challenges, particularly in acute myeloid leukemia (AML), ongoing research into new targets and combination therapies is expected to enhance the efficacy of BsAbs in relapsed or refractory (R/R) disease. This review explores the structural and functional innovations of BsAbs, the challenges in current therapies, and their transformative potential in hematological malignancy immunotherapy.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104752"},"PeriodicalIF":5.5,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CircRNAs in the tumor microenvironment: new frontiers in cancer progression and therapy 肿瘤微环境中的环状rna：癌症进展和治疗的新领域

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-05-02 DOI: 10.1016/j.critrevonc.2025.104754

Yipei Guo , Yuanxun Gong , Man Wu , Mengjia Ji , Fei Xie , Hao Chen , Haitao Niu , Chao Tang

{"title":"CircRNAs in the tumor microenvironment: new frontiers in cancer progression and therapy","authors":"Yipei Guo , Yuanxun Gong , Man Wu , Mengjia Ji , Fei Xie , Hao Chen , Haitao Niu , Chao Tang","doi":"10.1016/j.critrevonc.2025.104754","DOIUrl":"10.1016/j.critrevonc.2025.104754","url":null,"abstract":"<div><div>The tumor microenvironment (TME), a dynamic ecosystem which including immune cells, cancer-associated fibroblasts (CAFs), endothelial cells, pericytes and acellular components, is orchestrating cancer progression through crosstalk between malignant cells and stromal components and increasingly recognized as a therapeutic frontier. Within this intricate network, circular RNAs (circRNAs) have emerged as pivotal regulators due to their unique covalently closed structures, which confer exceptional stability and multifunctional capabilities. This regulation is mediated through multiple mechanisms, such as acting as microRNA (miRNA) sponges, interacting with proteins, and, in certain instances, encoding functional peptides. The interaction between circRNAs and the TME not only affects cancer growth and metastasis but also influences immune evasion and therapeutic resistance. Elucidating the mechanisms by which circRNAs orchestrate these interactions is essential for identifying novel diagnostic biomarkers and developing effective therapeutic strategies. Such insights are expected to bridge gaps in current cancer biology, offering promising avenues for precision oncology and ultimately improving clinical outcomes for cancer patients.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104754"},"PeriodicalIF":5.5,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy 肿瘤引流淋巴结在肿瘤进展及免疫治疗中的作用及临床意义

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-04-30 DOI: 10.1016/j.critrevonc.2025.104745

Qian Xu , Jiahui Chu , Qinqin Hu , Yanheng Sun , Fan Jiang , Song Li , Lian Liu

{"title":"The role and clinical significance of tumor-draining lymph nodes in tumor progression and immunotherapy","authors":"Qian Xu , Jiahui Chu , Qinqin Hu , Yanheng Sun , Fan Jiang , Song Li , Lian Liu","doi":"10.1016/j.critrevonc.2025.104745","DOIUrl":"10.1016/j.critrevonc.2025.104745","url":null,"abstract":"<div><div>Tumor-draining lymph nodes (TDLNs) play a pivotal role in tumor growth and the immune response, activating immune cells such as CD8 + T cells and natural killer cells to combat tumors. However, tumors can subvert TDLNs to avoid immune attack. Initially, TDLNs stimulate a robust antitumor response, but as tumor evolve, they infiltrate with immunosuppressive cells that alter the TDLN environment and potentially promote metastasis. Immunotherapy, including immune checkpoint inhibitor (ICI), have emerged as a potential solution to this challenge by reconfiguring the TDLN environment to enhance immune responses and influence the immune status of the primary tumor. The integrity of the TDLNs is crucial for the efficacy of immunotherapy. Conventional surgery often removes TDLNs, but this may impede immune system function and the effectiveness of immunotherapy. It is therefore recommended that removal of TDLNs be considered after neoadjuvant treatment rather than before adjuvant treatment. Accurate identification of patients who require post-neoadjuvant TDLN removal and the determination of metastatic nodes is of paramount importance in tailoring treatment plans, optimizing of patient outcomes, and improving quality of life.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104745"},"PeriodicalIF":5.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should adjuvant treatments be escalated in node-positive HR+/HER2- patients achieving pCR and omitting axillary dissection? 淋巴结阳性的HR+/HER2-患者实现pCR并省略腋窝清扫，是否应该增加辅助治疗？

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-04-29 DOI: 10.1016/j.critrevonc.2025.104732

Maria Vita Sanò, Lorenza Marino, Giuseppina Rosaria Rita Ricciardi

引用次数: 0

Regulation of the CD8⁺ T cell and PDL1/PD1 axis in gastric cancer: Unraveling the molecular landscape CD8 + T细胞和PDL1/PD1轴在胃癌中的调控：揭开分子景观

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-04-28 DOI: 10.1016/j.critrevonc.2025.104750

Xin Yong , Dong Mu , Hua Ni, Xue Wang, Tongqin Zhang, Xing Chang, Sheng He, Dejiang Zhou

{"title":"Regulation of the CD8⁺ T cell and PDL1/PD1 axis in gastric cancer: Unraveling the molecular landscape","authors":"Xin Yong , Dong Mu , Hua Ni, Xue Wang, Tongqin Zhang, Xing Chang, Sheng He, Dejiang Zhou","doi":"10.1016/j.critrevonc.2025.104750","DOIUrl":"10.1016/j.critrevonc.2025.104750","url":null,"abstract":"<div><div>Gastric cancer (GC) remains a significant global health burden, mainly due to immune evasion mechanisms within its complex tumor microenvironment (TME). The interaction between CD8⁺ T cells and the PD1/PDL1 axis is central to these mechanisms. CD8⁺ T cells, key players in antitumor immunity, often exhibit impaired functionality in the GC TME, primarily due to PD1-mediated inhibitory signaling induced by PDL1 expressed on tumor and immune cells. Recent findings have elucidated intricate molecular interactions governing PD1 expression on CD8⁺ T cells and the modulation of PDL1 on tumor cells and immune cells by diverse signals such as cytokines, metabolic factors, and noncoding RNAs. While high PD1 expression typically indicates CD8⁺ T cell exhaustion and poor clinical outcomes, recent studies highlight scenarios where elevated PD1 levels correlate with preserved or enhanced T cell cytotoxic activity, suggesting nuanced regulatory pathways. Therapeutic strategies that disrupt PD1/PDL1 interactions, through checkpoint inhibitors or pharmacological modulation, have demonstrated potential in reactivating antitumor responses. However, resistance mechanisms, including altered antigen presentation, metabolic reprogramming, and immunosuppressive cell infiltration, continue to limit efficacy. Emerging combination therapies, biomarker-driven patient stratification, and novel targets like noncoding RNAs and exosomal PDL1 represent promising avenues to enhance treatment effectiveness. This review synthesizes current insights into the molecular regulation of CD8⁺ T cell functionality and the PD1/PDL1 axis, highlighting potential therapeutic strategies to restore antitumor immunity and improve patient outcomes in gastric cancer.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104750"},"PeriodicalIF":5.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143937052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering 革命性的免疫疗法：CAR - t细胞工程的下一个前沿

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2025-04-28 DOI: 10.1016/j.critrevonc.2025.104751

Anuupama Suchiita , Subash Chandra Sonkar

{"title":"Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering","authors":"Anuupama Suchiita , Subash Chandra Sonkar","doi":"10.1016/j.critrevonc.2025.104751","DOIUrl":"10.1016/j.critrevonc.2025.104751","url":null,"abstract":"<div><div>Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a groundbreaking immunotherapy, offering new hope for cancer treatment, particularly in hematologic malignancies. This review explores the development of CAR T-cell therapy from its first-generation design, which laid the foundational structure, to advanced fifth-generation CARs that integrate sophisticated synthetic biology. Each generation of CARs has introduced critical improvements, such as the incorporation of costimulatory domains, dual signaling pathways, and cytokine release mechanisms to enhance T-cell activation, persistence, and efficacy. Current applications of CAR T-cell therapy have seen significant success in treating cancers like acute lymphoblastic leukemia and diffuse large B-cell lymphoma, with several therapies gaining regulatory approval. However, challenges persist in targeting solid tumors due to the immunosuppressive tumor microenvironment and antigen heterogeneity. Ongoing clinical trials and research are focused on overcoming these barriers through next-generation CAR designs, novel antigen targets, and combination therapies. The review highlights recent advancements, emerging targets, and the potential of CAR T-cell therapy to revolutionize cancer treatment, paving the way for more effective and personalized approaches.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"211 ","pages":"Article 104751"},"PeriodicalIF":5.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143906607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0